Healthcare Providers Acquire Financial Aid amid Ongoing COVID-19 Outbreak

Out-of-hospital care is anticipated to surge during the COVID-19 period. Stakeholders in the brucellosis vaccine market are increasing the availability of home healthcare providers, rehabilitation facilities, and long term care facilities. In-patient and community-based providers should review the current capacity for patients in both settings and plan for future pandemic-like situations.

Companies in the brucellosis vaccine market are scrambling to maintain robust supply chains to improve patient outcomes and meet demands. They are looking for financial aid by governments and organizing employee wellness programs to prevent & mitigate burnout, review pay & benefits compared with the industry average. Interrupted clinical research and clinical trial activities are now being conducted utilizing telehealth options wherever possible.

To know the scope of our report Get a Sample on Brucellosis Vaccine Market

Educational & Training Programs Help Control Brucellosis Disease in Colombia

Due to the presence of brucellosis in several susceptible production livestock systems scattered throughout Colombia, companies in the brucellosis vaccine market are making plans for its control, prevention, and eradication over the years. However, despite extensive efforts, brucellosis prevalence has fluctuated over the years without any trend of decreasing. Hence, companies are creating awareness about high impact educational and training programs required to address the disease in a comprehensive manner.

Companies in the Colombia brucellosis vaccine market are targeting vulnerable groups such as traditional smallholders, veterinary authorities, and communities in low productivity regions for their educational and training programs.

Get a glimpse of the in-depth analysis through our Report Brochure

India Holds Lucrative Incremental Opportunities for Brucellosis Vaccine Manufacturers

The global brucellosis vaccine market is projected to grow at a CAGR of 4% during the forecast period. Companies are tapping value-grab opportunities in India, since the Animal Husbandry Department in Yadgir has planned to vaccinate cattle and buffalo calves to prevent brucellosis disease under the National Animal Disease Control Programme (NADCP). Several thousand cattle and buffalo calves are being vaccinated under this flagship scheme launched by the Union Government of India.

Since brucellosis is a serious infectious disease that can cause abortion or loss of reproductivity, companies in the India brucellosis vaccine market are increasing output capacities to improve clinical outcomes in cattle and buffalo. Mass inoculation of cattle and buffalo is being conducted on priority in India to prevent the spread of the disease from animals to human beings.

Guinea Pig Model Holds Promising Potentials to Develop Well-tolerated Brucellosis Vaccines

Apart from developing vaccines for animals, companies in the brucellosis vaccine market are diversifying their research capabilities to innovate in vaccines for humans.

In order to develop new vaccine candidates, there is a need to comply with the set industry standards before selecting the viral vectors and the method for preparing & using the vaccine. Companies are increasing their R&D capabilities using the study of protection of the vaccine with the help of guinea pigs, including various options for administering, dose, and frequency. They are innovating in brucellosis vaccines that can be well-tolerated in humans by upgrading the production technology and testing in healthcare practice.

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Stakeholders in the brucellosis vaccine market are reviewing financial assistance programs associated with COVID-19 appropriations for eligibility. Restricted budgets for brucellosis control in Colombia is affecting the overall animal welfare in the region. Hence, stakeholders in Colombia should increase efforts for important financial investments based on sustained cooperation between governmental institutions, industry, and farmers for developing affordable and effective strategies to control the disease. On-farm detection involves the use of a screening test, followed by a confirmatory test. Testing is mandatory for international trade, animal movements in Colombia, and for clinically suspected animals. This involves the Rose Bengal Plate Test (RBPT) or Indirect ELISA as a screening test.

Brucellosis Vaccine Market: Overview

  • Brucellosis, often referred as Bang's disease, contagious abortion, or infectious abortion, affects cattle, buffaloes, sheep, goats, camels, pigs, dogs, horses, deer, yaks, and feral animals as well as humans. The disease causes considerable economic loss and is a serious public health concern.
  • Various types of brucellosis species are found in different kinds of animals including Brucella abortus (from cattle), Brucella abortus (from cattle), Brucella abortus (from cattle), Brucella abortus (from cattle), and others
  • Rise in prevalence of brucellosis and increase in awareness among people are projected to drive the global brucellosis vaccine market during the forecast period

Brucellosis Vaccine Market: Key Drivers

  • Most human zoonotic infections are transmitted by livestock. Zoonotic diseases account for 61% of the total animal diseases. For instance, brucellosis and foot-and-mouth are the major diseases in animals. Increase in number of cases of brucellosis propels the global brucellosis vaccine market. Rise in the number of brucellosis cases in India, Brazil, Mexico, and other countries is likely to drive the global market. The global burden of human brucellosis is quite high. Over 500,000 infections are caused by animals across the world every year.
  • Awareness about animal diseases, their symptoms, and medications is most important for livestock owners. Several animal health awareness programs have been conducted to increase awareness among people. In India, the National Animal Disease Control Programme (NADCP) is a flagship scheme launched by Honorable Prime Minister in September 2019 for control of foot & mouth disease and brucellosis by vaccinating 100% cattle, buffalo, sheep, goat, and pig population against FMD and 100% bovine female calves of four to eight months of age against brucellosis.

Brucellosis Vaccine Market: Segmentation

  • In terms of type, the global brucellosis vaccine market has been classified into RB51 vaccine, S19 vaccine, and others
  • Based on vaccine type, the global brucellosis vaccine market has been categorized into DNA vaccine, subunit vaccine, vector vaccine, and recombinant vaccine
  • In terms of application, the global brucellosis vaccine market has been segregated into cattle, sheep & goat, and others
  • Based on distribution channel, the global brucellosis vaccine market has been divided into veterinary hospitals & clinics, retail channels, and others
  • Each of the segments has been analyzed in detail for brucellosis vaccine trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The brucellosis vaccine market report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2031, considering 2020 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2021 to 2031, along with market size estimations.

Brucellosis Vaccine Market: Regional Overview

  • In terms of region, the global brucellosis vaccine market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • Asia Pacific accounted for the largest share of the global brucellosis vaccine market in 2020 and the trend is projected to continue during the forecast period. Growth of the brucellosis vaccine market in the region can be ascribed to presence of major players and high cattle population.
  • Asia Pacific is anticipated to gain market share during the forecast period. Product launches, acquisitions, distribution agreements, alliances, and geographical expansion by local players, especially in China and India, are expected to propel the brucellosis vaccine market in the region.
  • The current and future market sizes in terms of value (US$ Mn) of these regional markets and major countries have been provided in the report for the period from 2017 to 2031 along with CAGRs for the period from 2021 to 2031
  • The study also offers a list of recommendations, highlights, and useful insights of the market, which are likely to help new companies willing to enter the market and existing companies to increase market share and in the decision-making process

Major Players

  • The report concludes with the company profiles section, which includes key information about the major players in the global brucellosis vaccine market
  • Leading players analyzed in the report are
    • Merck Animal Health
    • Ceva Sante Animale
    • CZ Vaccines
    • Colorado Serum Company
    • Indian Immunologicals Ltd.
    • Hester Biosciences Limited
    • Veterinary Technologies Corporation
    • Fivet Animal Health
    • Jordan Bio-industries Center
    • Laboratories Tornel
  • Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Brucellosis Vaccine Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 253.1 Mn

Market Forecast Value in 2031

US$ 387.4 Mn

Growth Rate (CAGR)

4%

Forecast Period

2021–2031

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2020)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • By Type
    • RB51 Vaccine
    • S19 Vaccine
    • Others
  • By Vaccine Type
    • DNA Vaccine
    • Subunit Vaccine
    • Vector Vaccine
    • Recombinant Vaccine
  • By Application
    • Cattle
    • Sheep & Goat
    • Others
  • By Distribution Channel
    • Veterinary Hospitals & Clinics
    • Retail Channels
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Merck Animal Health
  • CEVA SANTE ANIMALE
  • CZ Vaccines
  • Colorado Serum Company
  • Indian Immunologicals Ltd.
  • Hester Biosciences Limited
  • Veterinary Technologies Corporation
  • Fivet Animal Health
  • Jordan Bio-industries Center
  • Laboratories Tornel

Customization Scope

Available upon request

Pricing

Available upon request

Brucellosis Vaccine Market – Scope of Report

TMR’s report on the global brucellosis vaccine market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides revenue of the global brucellosis vaccine market for the period of 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global brucellosis vaccine market from 2021 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global brucellosis vaccine market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global brucellosis vaccine market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global brucellosis vaccine market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global brucellosis vaccine market.

The report delves into the competitive landscape of the global brucellosis vaccine market. Key players operating in the global brucellosis vaccine market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global brucellosis vaccine market profiled in this report.

Key Questions Answered in Brucellosis Vaccine Market Report

  • What is the sales/revenue generated by brucellosis vaccines across all regions during the forecast period?
  • What are the opportunities in the global brucellosis vaccine market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which type is expected to generate the highest revenue globally in 2031? Which segment is projected to expand at the highest CAGR during the forecast period?
  • What is the market position of different companies operating in the global market?

Brucellosis Vaccine Market – Research Objectives and Research Approach

The comprehensive report on the global brucellosis vaccine market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives of this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global brucellosis vaccine market in terms of type, vaccine type, application, distribution channel, and region. Key segments under each criteria are studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global brucellosis vaccine market.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Brucellosis Vaccine Market – Segmentation

TMR’s study on the global brucellosis vaccine market includes information divided into five segments: type, vaccine type, application, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global brucellosis vaccine market are discussed in detail.

Type
  • RB51 Vaccine
  • S19 Vaccine
  • Others
Vaccine Type
  • DNA Vaccine
  • Subunit Vaccine
  • Vector Vaccine
  • Recombinant Vaccine
Application
  • Cattle
  • Sheep & Goat
  • Others
Distribution Channel
  • Veterinary Hospitals & Clinics
  • Retail Channels
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface

    1.1. Report Scope and Market Segmentation

    1.2. Research Highlights

2. Assumptions and Research Methodology

    2.1. Assumptions and Acronyms Used

    2.2. Research Methodology

3. Executive Summary

4. Market Overview

    4.1. Introduction

    4.2. Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunity

    4.3. Global Brucellosis Vaccine Market Forecast

    4.4. Global Brucellosis Vaccine Market Outlook

5. Market Outlook

    5.1. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)

    5.2. Disease Prevalence globally with key countries

    5.3. Regulatory Scenario

    5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Brucellosis Vaccine Market Analysis and Forecast, by Type

    6.1. Introduction

    6.2. Global Brucellosis Vaccine Market Value Share Analysis, by Type

    6.3. Global Brucellosis Vaccine Market Forecast, by Type

        6.3.1. RB51 Vaccine

        6.3.2. S19 Vaccine

        6.3.3. Others

    6.4. Global Brucellosis Vaccine Market Analysis, by Type

    6.5. Global Brucellosis Vaccine Market Attractiveness Analysis, by Type

7. Global Brucellosis Vaccine Market Analysis and Forecast, by Vaccine Type

    7.1. Introduction

    7.2. Global Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type

    7.3. Global Brucellosis Vaccine Market Forecast, by Vaccine Type

        7.3.1. DNA Vaccine

        7.3.2. Subunit Vaccine

        7.3.3. Vector Vaccine

    7.4. Recombinant Vaccine

    7.5. Global Brucellosis Vaccine Market Analysis, by Vaccine Type

    7.6. Global Brucellosis Vaccine Market Attractiveness Analysis, by Vaccine Type

8. Global Brucellosis Vaccine Market Analysis and Forecast, by Application

    8.1. Introduction

    8.2. Global Brucellosis Vaccine Market Value Share Analysis, by Application

    8.3. Global Brucellosis Vaccine Market Forecast, by Application

        8.3.1. Cattle

        8.3.2. Sheep & Goat

        8.3.3. Others

    8.4. Global Brucellosis Vaccine Market Analysis, by Application

    8.5. Global Brucellosis Vaccine Market Attractiveness Analysis, by Application

9. Global Brucellosis Vaccine Market Analysis and Forecast, by Distribution Channel

    9.1. Introduction

    9.2. Global Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel

    9.3. Global Brucellosis Vaccine Market Forecast, by Distribution Channel

        9.3.1. Veterinary Hospitals & Clinics

        9.3.2. Retail Channels

        9.3.3. Others

    9.4. Global Brucellosis Vaccine Market Analysis, by Distribution Channel

    9.5. Global Brucellosis Vaccine Market Attractiveness Analysis, by Distribution Channel

10. Global Brucellosis Vaccine Market Analysis, by Region

    10.1. Global Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Region

    10.2. Global Brucellosis Vaccine Market Forecast, by Region

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

11. North America Brucellosis Vaccine Market Analysis

    11.1. North America Brucellosis Vaccine Market Overview

    11.2. North America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Country

    11.3. North America Brucellosis Vaccine Market Forecast, by Country

        11.3.1. U.S.

        11.3.2. Canada

    11.4. North America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Type

    11.5. North America Brucellosis Vaccine Market Forecast, by Type

        11.5.1. RB51 Vaccine

        11.5.2. S19 Vaccine

        11.5.3. Others

    11.6. North America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Vaccine Type

    11.7. North America Brucellosis Vaccine Market Forecast, by Vaccine Type

        11.7.1. DNA Vaccine

        11.7.2. Subunit Vaccine

        11.7.3. Vector Vaccine

        11.7.4. Recombinant Vaccine

    11.8. North America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Application

    11.9. North America Brucellosis Vaccine Market Forecast, by Application

        11.9.1. Cattle

        11.9.2. Sheep & Goat

        11.9.3. Others

    11.10. North America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Distribution Channel

    11.11. North America Brucellosis Vaccine Market Forecast, by Distribution Channel

        11.11.1. Veterinary Hospitals & Clinics

        11.11.2. Retail Channels

        11.11.3. Others

12. Europe Brucellosis Vaccine Market Analysis

    12.1. Europe Brucellosis Vaccine Market Overview

    12.2. Europe Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Country/Sub-region

    12.3. Europe Brucellosis Vaccine Market Forecast, by Country/Sub-region

        12.3.1. Germany

        12.3.2. U.K.

        12.3.3. France

        12.3.4. Spain

        12.3.5. Italy

        12.3.6. Rest of Europe

    12.4. Europe Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Type

    12.5. Europe Brucellosis Vaccine Market Forecast, by Type

        12.5.1. RB51 Vaccine

        12.5.2. S19 Vaccine

        12.5.3. Others

    12.6. Europe Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Vaccine Type

    12.7. Europe Brucellosis Vaccine Market Forecast, by Vaccine Type

        12.7.1. DNA Vaccine

        12.7.2. Subunit Vaccine

        12.7.3. Vector Vaccine

        12.7.4. Recombinant Vaccine

    12.8. Europe Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Application

    12.9. Europe Brucellosis Vaccine Market Forecast, by Application

        12.9.1. Cattle

        12.9.2. Sheep & Goat

        12.9.3. Others

    12.10. Europe Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Distribution Channel

    12.11. Europe Brucellosis Vaccine Market Forecast, by Distribution Channel

        12.11.1. Veterinary Hospitals & Clinics

        12.11.2. Retail Channels

        12.11.3. Others

13. Asia Pacific Brucellosis Vaccine Market Analysis

    13.1. Asia Pacific Brucellosis Vaccine Market Overview

    13.2. Asia Pacific Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Country/Sub-region

    13.3. Asia Pacific Brucellosis Vaccine Market Forecast, by Country/Sub-region

        13.3.1. China

        13.3.2. Japan

        13.3.3. India

        13.3.4. Australia & New Zealand

        13.3.5. Rest of Asia Pacific

    13.4. Asia Pacific Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Type

    13.5. Asia Pacific Brucellosis Vaccine Market Forecast, by Type

        13.5.1. RB51 Vaccine

        13.5.2. S19 Vaccine

        13.5.3. Others

    13.6. Asia Pacific Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Vaccine Type

    13.7. Asia Pacific Brucellosis Vaccine Market Forecast, by Vaccine Type

        13.7.1. DNA Vaccine

        13.7.2. Subunit Vaccine

        13.7.3. Vector Vaccine

        13.7.4. Recombinant Vaccine

    13.8. Asia Pacific Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Application

    13.9. Asia Pacific Brucellosis Vaccine Market Forecast, by Application

        13.9.1. Cattle

        13.9.2. Sheep & Goat

        13.9.3. Others

    13.10. Asia Pacific Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Distribution Channel

    13.11. Asia Pacific Brucellosis Vaccine Market Forecast, by Distribution Channel

        13.11.1. Veterinary Hospitals & Clinics

        13.11.2. Retail Channels

        13.11.3. Others

14. Latin America Brucellosis Vaccine Market Analysis

    14.1. Latin America Brucellosis Vaccine Market Overview

    14.2. Latin America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Country/Sub-region

    14.3. Latin America Brucellosis Vaccine Market Forecast, by Country/Sub-region

        14.3.1. Brazil

        14.3.2. Mexico

        14.3.3. Rest of Latin America

    14.4. Latin America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Type

    14.5. Latin America Brucellosis Vaccine Market Forecast, by Type

        14.5.1. RB51 Vaccine

        14.5.2. S19 Vaccine

        14.5.3. Others

    14.6. Latin America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Vaccine Type

    14.7. Latin America Brucellosis Vaccine Market Forecast, by Vaccine Type

        14.7.1. DNA Vaccine

        14.7.2. Subunit Vaccine

        14.7.3. Vector Vaccine

        14.7.4. Recombinant Vaccine

    14.8. Latin America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Application

    14.9. Latin America Brucellosis Vaccine Market Forecast, by Application

        14.9.1. Cattle

        14.9.2. Sheep & Goat

        14.9.3. Others

    14.10. Latin America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Distribution Channel

    14.11. Latin America Brucellosis Vaccine Market Forecast, by Distribution Channel

        14.11.1. Veterinary Hospitals & Clinics

        14.11.2. Retail Channels

        14.11.3. Others

15. Middle East & Africa Brucellosis Vaccine Market Analysis

    15.1. Middle East & Africa Brucellosis Vaccine Market Overview

    15.2. Middle East & Africa Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Country/Sub-region

    15.3. Middle East & Africa Brucellosis Vaccine Market Forecast, by Country/Sub-region

        15.3.1. GCC Countries

        15.3.2. South Africa

        15.3.3. Rest of Middle East & Africa

    15.4. Middle East & Africa Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Type

    15.5. Middle East & Africa Brucellosis Vaccine Market Forecast, by Type

        15.5.1. RB51 Vaccine

        15.5.2. S19 Vaccine

        15.5.3. Others

    15.6. Middle East & Africa Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Vaccine Type

    15.7. Middle East & Africa Brucellosis Vaccine Market Forecast, by Vaccine Type

        15.7.1. DNA Vaccine

        15.7.2. Subunit Vaccine

        15.7.3. Vector Vaccine

        15.7.4. Recombinant Vaccine

    15.8. Middle East & Africa Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Application

    15.9. Middle East & Africa Brucellosis Vaccine Market Forecast, by Application

        15.9.1. Cattle

        15.9.2. Sheep & Goat

        15.9.3. Others

    15.10. Middle East & Africa Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Distribution Channel

    15.11. Middle East & Africa Brucellosis Vaccine Market Forecast, by Distribution Channel

        15.11.1. Veterinary Hospitals & Clinics

        15.11.2. Retail Channels

        15.11.3. Others

16. Competition Landscape

    16.1. Company Profiles

        16.1.1. Merck Animal Health

            16.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.1.2. Product Portfolio

            16.1.1.3. Financial Overview

            16.1.1.4. SWOT Analysis

            16.1.1.5. Strategic Overview

        16.1.2. Ceva Sante Animale

            16.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.2.2. Product Portfolio

            16.1.2.3. SWOT Analysis

            16.1.2.4. Strategic Overview

        16.1.3. CZ Vaccines

            16.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.3.2. Product Portfolio

            16.1.3.3. SWOT Analysis

            16.1.3.4. Strategic Overview

        16.1.4. Colorado Serum Company

            16.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.4.2. Product Portfolio

            16.1.4.3. SWOT Analysis

            16.1.4.4. Strategic Overview

        16.1.5. Indian Immunologicals Ltd.

            16.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.5.2. Product Portfolio

            16.1.5.3. SWOT Analysis

            16.1.5.4. Strategic Overview

        16.1.6. Hester Biosciences Limited

            16.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.6.2. Product Portfolio

            16.1.6.3. Financial Overview

            16.1.6.4. SWOT Analysis

            16.1.6.5. Strategic Overview

        16.1.7. Veterinary Technologies Corporation.

            16.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.7.2. Product Portfolio

            16.1.7.3. SWOT Analysis

            16.1.7.4. Strategic Overview

        16.1.8. Fivet Animal Health

            16.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.8.2. Product Portfolio

            16.1.8.3. SWOT Analysis

            16.1.8.4. Strategic Overview

        16.1.9. Jordan Bio-industries Center

            16.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.9.2. Product Portfolio

            16.1.9.3. SWOT Analysis

            16.1.9.4. Strategic Overview

        16.1.10. Laboratories Tornel

            16.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.1.10.2. Product Portfolio

            16.1.10.3. SWOT Analysis

            16.1.10.4. Strategic Overview

List of Tables

Table 01: Global Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Type, 2018–2030

Table 02: Global Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2017–2031

Table 03: Global Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 04: Global Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 05: Global Brucellosis Vaccine Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 06: North America Brucellosis Vaccine Market Revenue (US$ Mn) Forecast, by Country, 2017–2031

Table 07: North America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 08: North America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2017–2031

Table 09: North America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 10: North America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 11: Europe Brucellosis Vaccine Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 12: Europe Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 13: Europe Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2017–2031

Table 14: Europe Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 15: Europe Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 16: Asia Pacific Brucellosis Vaccine Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Asia Pacific Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 18: Asia Pacific Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2017–2031

Table 19: Asia Pacific Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 20: Asia Pacific Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Latin America Brucellosis Vaccine Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Latin America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 23: Latin America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2017–2031

Table 24: Latin America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 25: Latin America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 26: Middle East & Africa Brucellosis Vaccine Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 27: Middle East & Africa Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 28: Middle East & Africa Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2017–2031

Table 29: Middle East & Africa Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 30: Middle East & Africa Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global Brucellosis Vaccine Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Brucellosis Vaccine Market Value Share, by Type, 2020

Figure 03: Global Brucellosis Vaccine Market Value Share, by Vaccine Type, 2020

Figure 04: Global Brucellosis Vaccine Market Value Share, by Region, 2020

Figure 05: Global Brucellosis Vaccine Market Value Share, by Application, 2020

Figure 06: Global Brucellosis Vaccine Market Value Share, by Distribution Channel, 2020

Figure 07: Global Brucellosis Vaccine Market Value Share Analysis, by Type, 2020 and 2031

Figure 08: Global Brucellosis Vaccine Market Revenue (US$ Mn), by RB51 Vaccine, 2017–2031

Figure 09: Global Brucellosis Vaccine Market Revenue (US$ Mn), by S19 Vaccine, 2017–2031

Figure 10: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Others, 2017–2031

Figure 11: Global Brucellosis Vaccine Market Attractiveness Analysis, by Type, 2021–2031

Figure 12: Global Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type, 2020 and 2031

Figure 13: Global Brucellosis Vaccine Market Revenue (US$ Mn), by DNA Vaccine, 2017–2031

Figure 14: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Subunit Vaccine, 2017–2031

Figure 15: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Vector Vaccine, 2017–2031

Figure 16: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Recombinant Vaccine, 2017–2031

Figure 17: Global Brucellosis Vaccine Market Attractiveness Analysis, by Vaccine Type, 2021–2031

Figure 18: Global Brucellosis Vaccine Market Value Share Analysis, by Application, 2020 and 2031

Figure 19: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Cattle, 2017–2031

Figure 20: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Sheep & Goat, 2017–2031

Figure 21: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Others, 2017–2031

Figure 22: Global Brucellosis Vaccine Market Attractiveness Analysis, by Application, 2021–2031

Figure 23: Global Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 24: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Veterinary Hospitals & Clinics, 2017–2031

Figure 25: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Retail Channels, 2017–2031

Figure 26: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Others, 2017–2031

Figure 27: Global Brucellosis Vaccine Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 28: Global Brucellosis Vaccine Market Value Share Analysis, by Region, 2020 and 2031

Figure 29: Global Brucellosis Vaccine Market Analysis, by Region, 2021-2031

Figure 30: North America Brucellosis Vaccine Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 31: North America Brucellosis Vaccine Market Value Share (%), by Country, 2020 and 2031

Figure 32: North America Brucellosis Vaccine Market Attractiveness, by Country, 2021–2031

Figure 33: North America Brucellosis Vaccine Market Value Share Analysis, by Type, 2020 and 2031

Figure 34: North America Brucellosis Vaccine Market Attractiveness, by Type, 2021–2031

Figure 35: North America Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type, 2020 and 2031

Figure 36: North America Brucellosis Vaccine Market Attractiveness, by Vaccine Type, 2021–2031

Figure 37: North America Brucellosis Vaccine Market Value Share Analysis, by Application, 2020 and 2031

Figure 38: North America Brucellosis Vaccine Market Attractiveness, by Application, 2021–2031

Figure 39: North America Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 40: North America Brucellosis Vaccine Market Attractiveness, by Distribution Channel, 2021–2031

Figure 41: Europe Brucellosis Vaccine Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 42: Europe Brucellosis Vaccine Market Value Share (%), by Country/Sub-region, 2020 and 2031

Figure 43: Europe Brucellosis Vaccine Market Attractiveness, by Country/Sub-region, 2021–2031

Figure 44: Europe Brucellosis Vaccine Market Value Share Analysis, by Type, 2020 and 2031

Figure 45: Europe Brucellosis Vaccine Market Attractiveness, by Type, 2021–2031

Figure 46: Europe Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type, 2020 and 2031

Figure 47: Europe Brucellosis Vaccine Market Attractiveness, by Vaccine Type, 2021–2031

Figure 48: Europe Brucellosis Vaccine Market Value Share Analysis, by Application, 2020 and 2031

Figure 49: Europe Brucellosis Vaccine Market Attractiveness, by Application, 2021–2031

Figure 50: Europe Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 51: Europe Brucellosis Vaccine Market Attractiveness, by Distribution Channel, 2021–2031

Figure 52: Asia Pacific Brucellosis Vaccine Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 53: Asia Pacific Brucellosis Vaccine Market Value Share (%), by Country/Sub-region, 2020 and 2031

Figure 54: Asia Pacific Brucellosis Vaccine Market Attractiveness, by Country/Sub-region, 2021–2031

Figure 55: Asia Pacific Brucellosis Vaccine Market Value Share Analysis, by Type, 2020 and 2031

Figure 56: Asia Pacific Brucellosis Vaccine Market Attractiveness, by Type, 2021–2031

Figure 57: Asia Pacific Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type, 2020 and 2031

Figure 58: Asia Pacific Brucellosis Vaccine Market Attractiveness, by Vaccine Type, 2021–2031

Figure 59: Asia Pacific Brucellosis Vaccine Market Value Share Analysis, by Application, 2020 and 2031

Figure 60: Asia Pacific Brucellosis Vaccine Market Attractiveness, by Application, 2021–2031

Figure 61: Asia Pacific Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 62: Asia Pacific Brucellosis Vaccine Market Attractiveness, by Distribution Channel, 2021–2031

Figure 63: Latin America Brucellosis Vaccine Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 64: Latin America Brucellosis Vaccine Market Value Share (%), by Country/Sub-region, 2020 and 2031

Figure 65: Latin America Brucellosis Vaccine Market Attractiveness, by Country/Sub-region, 2021–2031

Figure 66: Latin America Brucellosis Vaccine Market Value Share Analysis, by Type, 2020 and 2031

Figure 67: Latin America Brucellosis Vaccine Market Attractiveness, by Type, 2021–2031

Figure 68: Latin America Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type, 2020 and 2031

Figure 69: Latin America Brucellosis Vaccine Market Attractiveness, by Vaccine Type, 2021–2031

Figure 70: Latin America Brucellosis Vaccine Market Value Share Analysis, by Application, 2020 and 2031

Figure 71: Latin America Brucellosis Vaccine Market Attractiveness, by Application, 2021–2031

Figure 72: Latin America Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 73: Latin America Brucellosis Vaccine Market Attractiveness, by Distribution Channel, 2021–2031

Figure 74: Middle East & Africa Brucellosis Vaccine Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 75: Middle East & Africa Brucellosis Vaccine Market Value Share (%), by Country/Sub-region, 2020 and 2031

Figure 76: Middle East & Africa Brucellosis Vaccine Market Attractiveness, by Country/Sub-region, 2021–2031

Figure 77: Middle East & Africa Brucellosis Vaccine Market Value Share Analysis, by Type, 2020 and 2031

Figure 78: Middle East & Africa Brucellosis Vaccine Market Attractiveness, by Type, 2021–2031

Figure 79: Middle East & Africa Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type, 2020 and 2031

Figure 80: Middle East & Africa Brucellosis Vaccine Market Attractiveness, by Vaccine Type, 2021–2031

Figure 81: Middle East & Africa Brucellosis Vaccine Market Value Share Analysis, by Application, 2020 and 2031

Figure 82: Middle East & Africa Brucellosis Vaccine Market Attractiveness, by Application, 2021–2031

Figure 83: Middle East & Africa Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 84: Middle East & Africa Brucellosis Vaccine Market Attractiveness, by Distribution Channel, 2021–2031

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Brucellosis Vaccines Market